Back to articles
Comparative guide · 6 min read

Resveratrol vs Pterostilbene — the longevity stilbene cousins

Updated 2026-05-16 · Reviewed by SupplementScore editors · No sponsorships

Resveratrol is the famous polyphenol from red wine that became a sirtuin-activation centerpiece in the early 2000s; pterostilbene is its dimethylated cousin from blueberries with substantially better oral bioavailability. The bioavailability difference is the most-cited reason to switch from resveratrol to pterostilbene. But in humans, neither has compelling outcome-level trial evidence: the resveratrol cardiovascular and glucose-control trials have been mixed, mostly small, and frequently surrogate-endpoint. Pterostilbene has even less human data. The honest read is that both sit in Tier 3 — interesting mechanism, sparse outcome data, modest expectations are warranted.

Quick verdict

GoalBetter choiceWhy
Established cardiovascular endpoint reductionNeither (use what's proven)Statins, blood pressure control, and exercise have the outcome data — stilbenes don't.
Sirtuin activation in vivo (mechanistic)PterostilbeneBetter bioavailability translates to higher serum and tissue concentrations.
Pure cost optimisationResveratrolCheaper per gram; if mechanism is what you're paying for, resveratrol is the entry product.
LDL elevation concernResveratrolRiche 2014 reported pterostilbene increased LDL-C at 250 mg/day; resveratrol does not show this signal.
In an NMN/NR longevity stackEither, low expectationsMechanistic synergy is theorised but human stack trials are absent.
Antioxidant from foodNeither — eat berries and red grapesDietary stilbene intake is small but comes with the rest of the food's nutrient profile.

How they compare on biology

Chemistry and bioavailability

Resveratrol (3,5,4'-trihydroxystilbene) and pterostilbene (3,5-dimethoxy-4'-hydroxystilbene) differ in two methylated hydroxyl groups. The methylation makes pterostilbene more lipophilic and dramatically reduces first-pass glucuronidation. Oral bioavailability: resveratrol ~1% as parent compound (rapidly conjugated to glucuronides and sulfates in liver); pterostilbene ~80% parent compound. Half-life: resveratrol ~9–14 hours of conjugates; pterostilbene ~105 minutes parent. For an SIRT1-activation mechanism that depends on tissue concentration of parent compound, this is a meaningful difference.

The sirtuin / longevity claim

Sinclair and colleagues popularised the resveratrol-as-SIRT1-activator hypothesis in 2003. Subsequent in vitro work showed the original SIRT1 activation may have been a fluorescent peptide artifact, and direct SIRT1 binding is now questioned. The current view: resveratrol and pterostilbene exert effects through multiple pathways (AMPK activation, NF-κB modulation, mitochondrial biogenesis upregulation, antioxidant scavenging), with SIRT1 as one possible contributor rather than the central mechanism.

Resveratrol human trial evidence

Cardiovascular: meta-analyses show modest reductions in systolic blood pressure (~3–5 mmHg) and some lipid effects at higher doses (≥500 mg/day); cardiovascular event endpoints are absent. Glucose control: small reductions in fasting glucose and HbA1c in T2DM users in some meta-analyses; effect size is modest and trial quality variable. Cognition: mixed signals in older adults; no compelling clinical endpoint. The picture is "directional" rather than "evidence-based."

Pterostilbene human trial evidence

Limited. Riche 2014 (n=80, 250 mg/day for 6–8 weeks) showed modest blood pressure reduction but a statistically significant LDL-C increase, the latter being a relevant cardiovascular concern. McCormack 2013 (n=80, same study) reported no significant effect on cognition or oxidative stress markers. Cognitive trials in older adults with pterostilbene are early-phase and small. The dataset cannot support general-population claims.

Dosing

Resveratrol typical supplement dose: 200–500 mg/day, trans-resveratrol form (not cis-resveratrol). Pterostilbene typical supplement dose: 50–250 mg/day; some longevity-stack products bundle 100 mg pterostilbene with 250–500 mg NMN. Higher resveratrol doses (500–1000 mg) are sometimes used in trials but with GI upset and the question of net benefit.

Safety

Both are generally well tolerated. Resveratrol: mild GI effects at high doses; theoretical anticoagulant effect — discuss with prescriber if on warfarin/NOACs. Pterostilbene: the Riche 2014 LDL-C signal is the most clinically relevant safety note; users on lipid-lowering therapy or with elevated cardiovascular risk should check lipid panels if using. Both: limited long-term safety data beyond 12 months.

Practical rule. If you want the longevity-stilbene mechanism with the best bioavailability and you don't have lipid concerns, pterostilbene 100–150 mg/day is reasonable. If you want the cheaper option with marginally more human data and a flatter cardiovascular profile, resveratrol 200–500 mg/day trans-isomer. If you're trying to optimise for outcomes that matter — cardiovascular events, all-cause mortality — neither has the trial evidence to justify a meaningful budget allocation. Pay for the proven things (statins if indicated, BP control, exercise, Mediterranean diet) first.

Who should consider supplementing

Users with a longevity-oriented stack who understand the evidence is mechanistic, not outcome-based, and are deploying it as a low-cost adjunct alongside the higher-evidence elements (exercise, sleep, dietary quality). Users in stilbene-poor dietary patterns who want a modest top-up.

Who should skip

Users with elevated LDL-C or on statins — avoid pterostilbene without lipid monitoring. Users on warfarin or NOACs — discuss before adding either stilbene. Users expecting cardiovascular outcome benefit from these compounds — the evidence does not support that expectation; reallocate budget to higher-evidence interventions.

What the price difference buys you

Resveratrol 250 mg/day runs $0.15–0.30/day at mid-market. Pterostilbene 100 mg/day runs $0.50–1/day; combined NMN+pterostilbene "longevity" stacks run $2–5/day. The cost gradient is steep and the evidence gradient is shallow — the per-dollar evidence is worse for the premium pterostilbene-based products.

What we'd actually buy

For most users: skip both as a paid supplement and eat berries, red grapes, and dark chocolate as the dietary stilbene source.

For users committed to a longevity stack: trans-resveratrol 250 mg/day from a reputable brand (Thorne, Doctor's Best, Pure Encapsulations) is the entry-level option. If you want the better-bioavailability route and don't have lipid concerns: pterostilbene 100 mg/day; check lipid panel at 6 months.

Sources

Read more: